LCI - Lannett Company, Inc.

NYSE - NYSE Delayed Price. Currency in USD
6.77
+0.28 (+4.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.49
Open6.52
Bid0.00 x 800
Ask0.00 x 800
Day's Range6.45 - 6.99
52 Week Range3.33 - 10.45
Volume823,882
Avg. Volume1,058,652
Market Cap266.221M
Beta (3Y Monthly)2.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Lannett Company (LCI) Stock Makes the Street Go Wild
    SmarterAnalyst

    Lannett Company (LCI) Stock Makes the Street Go Wild

    Generic pharmaceutical products provider Lannett Company (LCI) is a puzzle.Lannett shares jumped as much as 50% today, before trimming back some gains to trade up about 40%. Why? Your guess is as good as anybody else’s.SunTrust analyst Gregg Gilbert believes "management has been doing the right things to diversify the business and grow out of the levo trough." However, the analyst remains sidelined on the stock "pending greater visibility on the durability and profitability of the evolving portfolio and strategy to deal with the large debt load." The investigation into generic drug price fixing in the industry gives the analyst another reason to be worried about. But overall, the analyst believes that "this risk has taken more out of generic market caps than seems reasonable."Gilbert rates Lannett stock a Hold along with a $9.00 price target, which implies nearly 7% upside from current levels. (To watch Gilbert's track record, click here)BMO analyst Gary Nachman believes Lannett stock is worth $10 a share, the highest price target of any of the analysts recommending the stock today, though he rates the stock Neutral.Nachman stated, "LCI is executing well trying to manage through Levo loss and base erosion (typically mid-single digits, although some upside there in F2019). New product launches are expected to generate ~$75mm annually (F2019 on track for that), with about half expected from internal R&D and half from inlicensed products. Recently approved AB-rated Methylphenidate with partner Andor (launch late-June) and Thalidomide (addressing CRL, expected launch C2020) should be important contributors. Numbrino approval is expected by year-end, but LCI will cease unapproved C-topical sales ($3mm/qtr.) in August. On cost savings, LCI has completed all necessary actions and will finalize Cody Labs transition soon. LCI is proactively managing debt load (repurchased $24mm in open market, cash ~$205mm) and is confident in maintaining covenant compliance on 2020 debt."Ultimately, TipRanks reveals LCI as a stock that has not drawn a vote of confidence among Wall Street opinion. Out of 5 analysts polled in the last 12 months, all 5 rate the stock Hold/Neutral. Worthy of note, the 12-month average price target stands at $8.33, which aligns evenly with where the stock is currently trading. (See LCI's price targets and analyst ratings on TipRanks) More recent articles from Smarter Analyst: * Hedge Fund Legend Jim Simons Pours Money Into Aurora Cannabis (ACB) and Aphria (APHA) Stocks * 3 Healthcare Stocks to Fight Off the Market Flu * GrowGeneration (GRWG) Could Grow at Annual Rate of 100% * Is Apple (AAPL) Stock a Good Play With Tariff Delay?

  • MarketWatch

    UPDATE: Lannett stock up 40% with no news released; short interest stands at 74% of float

    Shares of generic-drug manufacturer Lannett Company Inc. shot up 40% in Monday afternoon trade. The company has not released any news that would account for the stock move, a spokesman for the company said. However, Lannet stock's short interest stood at at 20.66 million shares at the end of June, equal to 74.3% of the company's public float of 27.8 million shares. Ihor Dusaniwsky,managing director for predictive analytics at S3 Partners, a company that tracks short interest, said the move was not caused by a short squeeze, although it could trigger one if the stock keeps rallying. Short positions were down about $128,000 year-to-date, through Friday. "Shorts have taken a good stomach punch today, they're down $46.2 million," he said. "They are definitely a candidate for a short squeeze after today." Shares of Lannett have gained 67.9% in the year to date, while the S&P 500 has gained 19.2%.

  • Benzinga

    Option Trader Makes Bullish Bet On Lannett Rebound

    On Tuesday morning, Benzinga Pro subscribers received two options alerts related to Lannett. At 9:36 a.m., a trader bought 854 Lannett call options at a $7.50 strike price that expire on Sept. 20. At 9:42 a.m., likely the same trader bought another 752 Sept. 20 $7.50 Lannett call options at the ask price of 45.1 cents.

  • FDA rules in favor of Lannett in dispute over cocaine product
    American City Business Journals

    FDA rules in favor of Lannett in dispute over cocaine product

    The federal agency's ruling means its review of Lannett's new drug application for a topical cocaine hydrocholride product can continue.

  • Here’s What Hedge Funds Think About Lannett Company, Inc. (LCI)
    Insider Monkey

    Here’s What Hedge Funds Think About Lannett Company, Inc. (LCI)

    How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Lannett initiates human testing of biosimilar insulin product
    American City Business Journals

    Lannett initiates human testing of biosimilar insulin product

    The Northeast Philadelphia generic drug company is co-developing the biosimilar with a Chinese partner.

  • Is Lannett Co (LCI) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Lannett Co (LCI) Outperforming Other Medical Stocks This Year?

    Is (LCI) Outperforming Other Medical Stocks This Year?

  • Implied Volatility Surging for Lannett (LCI) Stock Options
    Zacks

    Implied Volatility Surging for Lannett (LCI) Stock Options

    Investors need to pay close attention to Lannett (LCI) stock based on the movements in the options market lately.

  • Top Ranked Value Stocks to Buy for May 16th
    Zacks

    Top Ranked Value Stocks to Buy for May 16th

    Top Ranked Value Stocks to Buy for May 16th

  • Here's Why Generic-Drug Manufacturers Were Down Monday
    Motley Fool

    Here's Why Generic-Drug Manufacturers Were Down Monday

    Forty-four states have brought a lawsuit against the industry.

  • Thomson Reuters StreetEvents

    Edited Transcript of LCI earnings conference call or presentation 6-May-19 8:30pm GMT

    Q3 2019 Lannett Company Inc Earnings Call

  • Lannett gets notice that probe into alleged generic drug price-fixing may widen
    American City Business Journals

    Lannett gets notice that probe into alleged generic drug price-fixing may widen

    The Northeast Philadelphia generic drug maker said it received written notice from various state Attorneys General that they intend to bring claims alleging price fixing and anti-competitive behavior involving more drug products.

  • Here's Why Lannett Company Stock Is Collapsing Today
    Motley Fool

    Here's Why Lannett Company Stock Is Collapsing Today

    Quarterly operating results were pretty good, but the business disclosed that it may face a lawsuit along with other makers of generic drugs.

  • Lannett Inc (LCI) Q3 2019 Earnings Call Transcript
    Motley Fool

    Lannett Inc (LCI) Q3 2019 Earnings Call Transcript

    LCI earnings call for the period ending March 31, 2019.

  • Lannett (LCI) Surpasses Q3 Earnings and Revenue Estimates
    Zacks

    Lannett (LCI) Surpasses Q3 Earnings and Revenue Estimates

    Lannett (LCI) delivered earnings and revenue surprises of 9.68% and 11.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Lannett: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the Philadelphia-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 68 cents per share. The results beat Wall ...

  • Benzinga

    Lannett Q3 Earnings Preview

    Lannett Co (NYSE: LCI ) unveils its next round of earnings this Monday, May 6. Get prepared with Benzinga's ultimate preview for Lannett's third-quarter earnings. Earnings and Revenue Lannett  EPS is expected ...

  • Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?

    Is (LCI) Outperforming Other Medical Stocks This Year?

  • Lannett to launch generic ADHD drug this quarter
    American City Business Journals

    Lannett to launch generic ADHD drug this quarter

    Lannett Co. Inc. said Tuesday it plans to launch a generic version of the attention deficit hyperactivity disorder drug Concerta later this quarter. The launch is the result of a licensing deal the Northeast Philadelphia generic drug company signed in August with Andor Pharmaceuticals of Florida for its extended-release methylphenidate hydrochloride tablets. Methylphenidate hydrochloride is the active ingredient in Concerta, which is marketed by a subsidiary of Johnson & Johnson.

  • Analysts Estimate Lannett (LCI) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Lannett (LCI) to Report a Decline in Earnings: What to Look Out for

    Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
    Zacks

    Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

    Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
    Zacks

    Lannett (LCI) to Report Q3 Earnings: What's in the Cards?

    Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches

  • Investors Who Bought Lannett Company (NYSE:LCI) Shares Five Years Ago Are Now Down 77%
    Simply Wall St.

    Investors Who Bought Lannett Company (NYSE:LCI) Shares Five Years Ago Are Now Down 77%

    Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow investors lose their hard-earned money. Anyone who held Lannett Company, Inc. (NYSE:LCI) for five years would...

  • Are Options Traders Betting on a Big Move in Lannett (LCI) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Lannett (LCI) Stock?

    Investors need to pay close attention to Lannett (LCI) stock based on the movements in the options market lately.

  • Lannett (LCI) Gains But Lags Market: What You Should Know
    Zacks

    Lannett (LCI) Gains But Lags Market: What You Should Know

    Lannett (LCI) closed at $8.05 in the latest trading session, marking a +0.06% move from the prior day.